Contribution of contaminant indium-114m/indium-114 to indium-111 oxine blood dosimetry.
Indium-114m and 114In appear as contaminants in commercial preparations of [111In]oxine at a level of about 0.05% at time of calibration (TOC). The contribution of these contaminants to the radiation absorbed dose from [111In]oxine leukocyte, platelet, and erythrocyte imaging procedures has been evaluated. When the absorbed dose from these contaminants is expressed as a percent of the 111In dose to the same organ from a given procedure, the contaminants contribute an additional 0.16 to 12% of the 111In dose, and in one case, that of the spleen from [111In]oxine labeled erythrocytes, they contribute an additional 33%. Commercial samples of aqueous-based [111In]oxine contain levels of 114mIn/114In sufficient to result in a mild to moderate increase in the absorbed radiation dose to the patient. Strict quality control procedures must be maintained by suppliers to prevent higher contamination levels. It is advisable to avoid using 111In products of this nature later than about 3 days after the time of calibration.
D001792:Blood Platelets; D004340:Drug Contamination; D004912:Erythrocytes; D006801:Humans; D006912:Hydroxyquinolines; D007204:Indium; D007962:Leukocytes; D009942:Organometallic Compounds; D015125:Oxyquinoline / Q000031:analogs & derivatives; D011829:Radiation Dosage; D011868:Radioisotopes
D006912:Hydroxyquinolines; D009942:Organometallic Compounds; D011868:Radioisotopes; D007204:Indium; C032950:indium oxine; D015125:Oxyquinoline